Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

Testosterone plays a critical role in male sexual functioning but can also impact bone mass, fat distribution, muscle mass, ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...